Summit Therapeutics Inc. (SMMT) stock
SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.50−0.17 (-1.59%)
Close on Nov 18, 2026Market cap $8.38BP/E –Yield –
Summit Therapeutics cash
Cash and short-term investments held at the end of each period.
Summit Therapeutics's cash was $690.68M at Jun 30, 2026. For fiscal 2025 it was $713.45M, up 72.9% from the year before. The highest annual figure on record is $713.45M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $713.45M | +72.9% |
| FY2024 | Dec 31, 2024 | $412.67M | +121.6% |
| FY2023 | Dec 31, 2023 | $186.24M | -71.3% |
| FY2022 | Dec 31, 2022 | $648.61M | +803.5% |
| FY2021 | Dec 31, 2021 | $71.79M | +103.7% |
| FY2019 | Jan 31, 2019 | $35.25M | +23.7% |
| FY2018 | Jan 31, 2018 | $28.50M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $690.68M | +131.9% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $598.73M | +65.7% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $713.45M | +72.9% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $238.55M | -51.0% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $297.87M | -8.5% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $361.32M | +130.6% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $412.67M | +121.6% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $486.90M | +144.7% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $325.47M | +51.4% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $156.68M | -35.2% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $186.24M | -71.3% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $198.95M | +63.1% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $215.01M | +275.0% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $241.93M | +212.4% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $648.61M | +803.5% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $121.97M | +52.0% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $57.34M | -44.5% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $77.45M | -24.2% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $71.79M | +103.7% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $80.25M | +181.6% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $103.39M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $102.19M | – |
| Q4 FY2019CQ4 2018 | Jan 31, 2019 | $35.25M | – |
| Q4 FY2018CQ4 2017 | Jan 31, 2018 | $28.50M | – |
See a number that looks wrong?